B cell–activating factor modulates the factor VIII immune response in hemophilia A

Inhibitors of factor VIII (FVIII) remain the most challenging complication of FVIII protein replacement therapy in hemophilia A (HA). Understanding the mechanisms that guide FVIII-specific B cell development could help identify therapeutic targets. The B cell–activating factor (BAFF) cytokine family...

Descripción completa

Detalles Bibliográficos
Autores principales: Doshi, Bhavya S., Rana, Jyoti, Castaman, Giancarlo, Shaheen, Mostafa A., Kaczmarek, Radoslaw, Butterfield, John S.S., Meeks, Shannon L., Leissinger, Cindy, Biswas, Moanaro, Arruda, Valder R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262462/
https://www.ncbi.nlm.nih.gov/pubmed/33651716
http://dx.doi.org/10.1172/JCI142906

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262462/
https://www.ncbi.nlm.nih.gov/pubmed/33651716
http://dx.doi.org/10.1172/JCI142906

Ejemplares similares